Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTK Inhibitor Rocbrutinib in Combination With BCL-2 Inhibitor Lacutoclax in Patients With B-Cell Malignancies

NCT07609862 is registered in ClinicalTrials.gov with Guangzhou Lupeng Pharmaceutical Company LTD. as lead sponsor.

NCT NCT07609862
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07609862 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTK Inhibitor Rocbrutinib in Combination With BCL-2 Inhibitor Lacutoclax in Patients With B-Cell Malignancies
Lead sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 14, 2026
Completion date
May 30, 2033
Enrollment
92 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma ( fl), mantle cell lymphoma (mcl), waldenström macroglobulinemia (wm)